NeoPHOEBE (BIG 6-11 / GBG 73)
Clinical Trial Program
A phase II, randomized, parallel cohort, two stage, double-blind, placebo-controlled study of neoadjuvant trastuzumab versus trastuzumab plus BKM120 (PI3K inhibitor) in combination with weekly paclitaxel in HER2-positive, PIK3CA wild-type and PIK3CA mutant primary breast cancer
Phase II
Status
Finished
Tumour subtype:
HER2+
Scenario
Neoadjuvant
SPONSOR
COLLABORATORS
PRINCIPAL INVESTIGATORS
Sherene Loi, MD, PhD (Peter MacCallum Cancer Centre)
Sibylle Loibl, MD (GBG Co-Chair and Associate Professor at the University of Frankfurt, Germany)
Sites
